AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32883721
Drug: Internet-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based intervention based on Acceptance and Commitment Therapy (ACT)
Trial: 33069664
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg caffeine
Trial: 34257088
Drug: Structured pharmacotherapy
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured pharmacotherapy optimisation intervention
Trial: 34197339
Drug: Homeopathic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic treatment (Berberis 6CH, Mercurius Solubilis/Belladona/Hepar Sulfur, Pyrogenium 200CH biotherapic) prescribed in diluted low ultra-diluted concentration doses for all signs and symptoms, with biotherapics used for chronic stimulation.
Trial: 34197339
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Conventional periodontal therapy without homeopathy)
Trial: 33153828
Drug: Quetiapine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (300 mg nightly)
Trial: 36062743
Drug: Netakimab (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netakimab (120 mg subcutaneous at weeks 0, 1, 2, and every other week thereafter)
Trial: 33036921
Drug: Pentoxifylline 400
RxNorm normalized name: pentoxifylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg, three times daily, for 9 doses within 72 hours of diagnosis
Trial: 36229048
Drug: Otilimab 90
RxNorm normalized name: Otilimab
DrugBank: Otilimab (DB06303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otilimab 90 mg plus standard care
Trial: 32376815
Drug: Normal daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal daily activities for 8 weeks
Trial: 34563635
Drug: Standard parotid-sparing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard parotid-sparing radiation therapy
Trial: 34563635
Drug: Stem cell
RxNorm normalized name: Stem cells, apheresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stem cell sparing (SCS) radiation therapy
Trial: 34196379
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL suction
Trial: 34196379
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL suction
Trial: 34898293
Drug: Menopausal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Menopausal hormone therapy (MHT) with exercise and education
Trial: 35608484
Drug: Liberal approach
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal approach to glucose control (IV insulin commenced at blood glucose >252 mg/dl, titrated to 180-252 mg/dl)
Trial: 35608484
Drug: Control approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control approach to glucose control (IV insulin commenced at blood glucose >180 mg/dl, titrated to 108-180 mg/dl)
Trial: 34022750
Drug: Topical capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical capsaicin (0.075%)
Trial: 33288086
Drug: Tazarotene 0.05%
RxNorm normalized name: TAZAROTENE 0.05% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazarotene 0.05% gel with NB-UVB
Trial: 36370871
Drug: Relugolix combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relugolix combination therapy (40 mg relugolix, 1 mg estradiol, and 0.5 mg norethindrone acetate once daily)
Trial: 39466126
Drug: Relugolix combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relugolix combination therapy
Trial: 33591141
Drug: SA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SA with morphine 0.1 mg (SA0.1)
Trial: 33591141
Drug: SA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SA with morphine 0.2 mg (SA0.2)
Trial: 33591141
Drug: Fascia iliaca
RxNorm normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fascia iliaca compartment block with dexamethasone 4 mg + levobupivacaine 0.375% 20 mL (FICB20)
Trial: 33591141
Drug: Fascia iliaca
RxNorm normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fascia iliaca compartment block with dexamethasone 4 mg + levobupivacaine 0.375% 30 mL (FICB30)
Trial: 33591141
Drug: Lateral femoral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral femoral cutaneous nerve block with levobupivacaine 0.25% 5 mL (LFCNB)
Trial: 33591141
Drug: Standardized analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized analgesia (intravenous metamizole magnesium, dexketoprofen, paracetamol, morphine, regional rescue)
Trial: 32771596
Drug: Nonresponders to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonresponders to mesh removal treatment.
Trial: 34964149
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg galantamine (acute administration)
Trial: 35725017
Drug: Postpartum diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postpartum diabetes screening (2-hour oral glucose tolerance test within 4-12 weeks postpartum)
Trial: 32320465
Drug: Ad26.RSV.preF low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.RSV.preF low-dose (LD; 5 × 10^10 vector particles)
Trial: 32320465
Drug: Ad26.RSV.preF high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.RSV.preF high-dose (HD; 1 × 10^11 vector particles)
Trial: 35781888
Drug: 3-day protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day protocol of systemic antibiotics (amoxicillin and metronidazole) 500mg 3-times-daily for 3 days, followed by placebo 3-times-daily for 4 days
Trial: 35781888
Drug: 7-day protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day protocol of systemic antibiotics (amoxicillin and metronidazole) 500mg 3-times-daily for 7 days
Trial: 33176232
Drug: Pertuzumab (first-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pertuzumab (first-line therapy)
Trial: 33176232
Drug: Trastuzumab–taxane (first-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab–taxane (first-line therapy)
Trial: 35299035
Drug: T-DM1 (second-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-DM1 (second-line treatment)
Trial: 33176232
Drug: First-line treatment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line treatment for mBC
Trial: 33176232
Drug: Second-line treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line treatment for mBC
Trial: 33176232
Drug: Third-line treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third-line treatment for mBC
Trial: 33171419
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (hysterectomy, myomectomy, or UAE)
Trial: 35907513
Drug: Metformin 500mg
RxNorm normalized name: METFORMIN 500MG/SITAGLIPTIN 50MG TAB
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 500mg by mouth three times a day for 30 to 36 months
Trial: 32928570
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) associated with Stabilization Exercises (SE)
Trial: 34303323
Drug: Jyoti-Trataka yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Jyoti-Trataka yoga (daily 55-min sessions for one month)
Trial: 34303323
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (administered oral hypoglycemic drugs only)
Trial: 34303323
Drug: Between-group comparison
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Between-group comparison post-treatment
Trial: 36810360
Drug: Positive expiratory
RxNorm normalized name: AerobiKA Oscillating Positive Expiratory Pressure Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive expiratory pressure (PEP) therapy
Trial: 33332779
Drug: Tocilizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (8 mg per kilogram of body weight intravenously)
Trial: 32945218
Drug: Metformin (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1500 mg) plus myoinositol (4 g) per day
Trial: 32945218
Drug: Myoinositol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myoinositol (4 g) per day
Trial: 33090016
Drug: Fast acting
RxNorm normalized name: 4-Way Fast Acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast acting insulin aspart (FA)
Trial: 32623833
Drug: Micellar water,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micellar water, cream, and serum
Trial: 34928336
Drug: Pooled Higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pooled Higher Doses (PHD) group (≥1 000 IU/day, n = 349)
Trial: 34928336
Drug: Pooled Higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pooled Higher Doses (PHD) group (≥1 000 IU/day)
Trial: 32730089
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cervical (C3-C4), cervicothoracic (C7-T1) and thoracic spine (T5-T6) thrust joint manipulation
Trial: 32721948
Drug: ZNF217 targeting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZNF217 targeting with preexisting therapies, such as the Akt inhibitor triciribine
Trial: 32568205
Drug: Escitalopram (n=13;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (n=13; average dose=7.3 mg)
Trial: 32568205
Drug: Sertraline (n=11;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (n=11; average dose=31.8 mg)
Trial: 32568205
Drug: Nicergoline (n=9;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicergoline (n=9; average dose=14.5 mg)
Trial: 33723687
Drug: Vaginal fractional
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal fractional CO2 laser therapy
Trial: 33774639
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of collagen peptides (CP)
Trial: 33774639
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of collagen peptides (CP)
Trial: 33913736
Drug: Artesunate tablet
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate tablet (50 mg two times daily) combined with HAART
Trial: 35788775
Drug: Dietary advice
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary advice to isocalorically increase protein intake to ≥ 1.2 g/kg aBW/d (Protein + ; n = 84)
Trial: 35880828
Drug: Krill oil
RxNorm normalized name: Krill oil
DrugBank: Krill oil (DB16615)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krill oil (4 g/d; 0.60 g EPA/d, 0.28 g DHA/d, 0.45 g astaxanthin/d)
Trial: 35712946
Drug: Auricular bloodletting
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular bloodletting combined with auricular point sticking once a week for 4 weeks (treatment group 1)
Trial: 35712946
Drug: Auricular bloodletting
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular bloodletting combined with auricular point sticking twice a week for 4 weeks (treatment group 2)
Trial: 35712946
Drug: Auricular bloodletting
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular bloodletting combined with auricular point sticking three times a week for 4 weeks (treatment group 3)
Trial: 32740716
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care with daily traditional experiential music listening
Trial: 33201130
Drug: Intermittent Pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Pneumatic Compression (IPC) in addition to standard prophylaxis with anti-embolic stockings and low-molecular-weight heparin
Trial: 33970256
Drug: Depot buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot buprenorphine (weekly or monthly)
Trial: 33970256
Drug: Sublingual buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine (daily)
Trial: 32376759
Drug: Nasal fentanyl
RxNorm normalized name: fentanyl Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal fentanyl (NF) and buccal midazolam (BM) administered by family members
Trial: 32376759
Drug: Buccal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Buccal midazolam (BM) alone
Trial: 32376759
Drug: Standard breakthrough
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard breakthrough medication by nurses
Trial: 36510345
Drug: Buccal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal misoprostol
Trial: 36460236
Drug: Silver Modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver Modified Atraumatic Restorative Treatment (SMART)
Trial: 36351436
Drug: Genicular nerves
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genicular nerves block (20 ml ropivacaine 0.2%)
Trial: 36351436
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration analgesia (150 ml ropivacaine 0.2%)
Trial: 35869721
Drug: Root canal
RxNorm normalized name: Canal + Gel 10% for Root Canal Preparation Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Root canal therapy (RCT) (203 cases)
Trial: 36109696
Drug: Preventive treatment
RxNorm normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive treatment based on botulinum toxin or oral drugs after 3 months
Trial: 35461287
Drug: Standard measles
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard measles vaccine
Trial: 35379019
Drug: Triamcinolone Hexacetonide
RxNorm normalized name: Triamcinolone Hexacetonide
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone Hexacetonide (TH) 40 mg
Trial: 33017047
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg ketamine
Trial: 35276467
Drug: Saliravira® package
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saliravira® package plus routine treatments of COVID-19
Trial: 35276467
Drug: Routine treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatments of COVID-19 alone
Trial: 32486877
Drug: Serum total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum total bilirubin tertile 3 (12.9–34.1 μmol/L)
Trial: 32486877
Drug: Direct bilirubin
RxNorm normalized name: bilirubin preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct bilirubin tertile 3 (2.5–24.8 μmol/L)
Trial: 33555697
Drug: Exposure treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure treatment (10 to 15 sessions)
Trial: 35299177
Drug: Site-specific therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Site-specific therapy based on gene expression profiling (GEP)
Trial: 35595223
Drug: GnRHa alone
RxNorm normalized name: GnRH pharmaccine
DrugBank: GnRH pharmaccine (DB05815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRHa alone (0.2 mg of triptorelin)
Trial: 35595223
Drug: Dual trigger
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual trigger (0.2 mg of triptorelin plus 2000 IU of hCG)
Trial: 34735862
Drug: Targeted education
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted education on the use of oral HIV self-test kits for their partners, along with up to five oral HIV self-test kits.
Trial: 32430507
Drug: EPOCH-vorinostat (EPOCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPOCH-vorinostat (EPOCH plus 300 mg vorinostat on days 1 to 5 of each cycle)
Trial: 32430507
Drug: Low diagnosis-to-treatment
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low diagnosis-to-treatment interval (DTI)
Trial: 32430507
Drug: Preprotocol therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preprotocol therapy
Trial: 35983429
Drug: IV lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV lidocaine (1.5 mg kg−1 followed by 4 mg kg−1 h−1 continuous infusion)
Trial: 34759182
Drug: High-molecular-weight hyaluronate
RxNorm normalized name: High molecular weight insulin human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-molecular-weight hyaluronate injection (20 mg)
Trial: 34759182
Drug: Low-molecular-weight hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight hyaluronate injection (20 mg)
Trial: 34759182
Drug: Physical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Therapy (10 sessions)
Trial: 32660521
Drug: Low-volume preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume preparation
Trial: 32660521
Drug: High-volume preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume preparation
Trial: 38721650
Drug: Flexible take-home
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flexible take-home dosing buprenorphine/naloxone
Trial: 32691178
Drug: Low-dose methadone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methadone (LDM)
Trial: 34938043
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injections (BTX)
Trial: 38587822
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two doses)
Trial: 36483295
Drug: NESA neuromodulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NESA neuromodulation treatment (NNT)
Trial: 32282852
Drug: Metformin 1,700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1,700 mg/day
Trial: 32282852
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of linagliptin/metformin
Trial: 35664940
Drug: Acacia (Acacia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acacia (Acacia nilotica Linn.) pod's sitz bath (30g) plus vaginal cotton pessary (5 ml) once daily for 10 days
Trial: 35664940
Drug: Placebo (palm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (palm sugar powder 30g solution for sitz bath plus vaginal cotton pessary same as Acacia group)
Trial: 32538007
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus western medication (levamlodipine maleate 2.5 mg once daily)
Trial: 32538007
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus western medication
Trial: 32538007
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication (levamlodipine maleate 2.5 mg once daily)
Trial: 32719045
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous methylprednisolone (250 mg on day 1 followed by 80 mg on days 2-5) with or without tocilizumab (8 mg/kg body weight, single infusion) if respiratory condition did not improve sufficiently (in 43%).
Trial: 32719045
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous methylprednisolone with or without tocilizumab.
Trial: 34216815
Drug: Exemestane 25
RxNorm normalized name: exemestane 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane 25 mg/three times-week
Trial: 34216815
Drug: Exemestane 25
RxNorm normalized name: exemestane 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane 25 mg/once a week
Trial: 34216815
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (full dose arm)
Trial: 34216815
Drug: Circulating sex
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Circulating sex hormones
Trial: 32664003
Drug: Continuing sertraline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing sertraline